Mike joined Amicus Therapeutics in September 2017 as Senior Vice President, Business and Corporate Development. He brings many years of global experience in the pharmaceutical and biotechnology industries as well academic and clinical medicine. Prior to joining Amicus, Dr. Diem was Senior Vice President of Corporate and Business Development at Aevi Genomic Medicine, where he led all business development and licensing activities.
Previously, Mike was a Vice President at AstraZeneca, where he was responsible for driving business strategy, including mergers and acquisitions, divestitures, and investments to bolster the core growth platforms and therapy areas. His core responsibilities included corporate strategy, corporate development, and MedImmune Ventures.
Earlier, Mike was the Director of Business Development for GSK Rare Diseases for 3 years and was responsible for partnerships, licensing, and M&A. Before that, he was a Partner at SR One, the venture capital subsidiary of GlaxoSmithKline. Mike joined SROne as an associate in 2005, and during his tenure there he was responsible for many of the firm's investments and was a member or observer to the boards of Aileron Therapeutics, CalciMedica, Protez (acquired by Novartis), Synovex, Trinity Biosystems, and Nupathe.
Before joining SR One, Mike was an associate at Frantz Medical Ventures and practiced as an attending physician for 6 years.
Education, Personal, and Fellowship
Mike holds a BA in biological sciences from Rutgers University and an MBA from the Waterhead School of Management at Case Western Reserve University. Mike earned an MD from the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, and completed his residency training at Duke University Medical Center.
Mike is a member of Class 12 and served his fellowship at SR One under mentors Phil Smith and Russell Greig.